発表論文 - 2026年
- Sakamoto A, Noboruo I, Tateishi H, Tomita S, Fukuda T, Matsushima-Nagata K, Aoki M, Kusakari D, Masunaga T, Nishimura N, Ito T, Otsuka M, Fujita M, and Anraku K.
Anticancer activity of liposomes prepared solely from cardiolipin.
Lipids, in press.
- Otsuka M and Fujita M.
Structure-function study of symmetrically substituted pyridine derivatives based on the iron binding site of bleomycin.
Synlett, in press.
- Nakamura Y, Ahagon-Edamura A, Koga R, Shimagaki K, Uesugi M, Fujino H, Beyri B, Arakaki Y, Ciftci H, Masunaga T, Tateishi H, Otsuka M, Yamaguchi Y, and Fujita M.
Regulation of HIV-2 Vpx/Vpr expression by the poly-proline motif: Enhancement of protein dimerization and translation.
Virology 623: 111016, 2026.
- Badran MM, Beyri B, Tateishi H, Shimagaki K, Nakata A, Ito A, Nishimura N, Abbas SHH, Abdel-Aziz M, Otsuka M, Yoshida M, Fujita M, Brase S, and Radwan MO.
Harnessing substituted 4-chlorothieno[2,3-b]pyridine as a new cap for potent and selective antiproliferative HDAC inhibitors.
Pharmaceuticals 19: 442, 2026.
- Kato K, Yamaguchi Y, Ichimaru Y, Kajiyama M, Kato M, Nagatomo M, Jin W, Wachino JI, Arakawa Y, Fukuishi N, Fujita M, Otsuka M, and Kurosaki H.
Structure-guided evaluation of thiol-based fluorescent probes for selective detection and inhibition of metallo-β-lactamases.
Biological and Pharmaceutical Bulletin 49: 691-700, 2026.
- Sever B, Turkes C, Demir Y, Elamin KM, Osman W, Oral K, Genc SA, Canturk Z, Masunaga T, Kishimoto N, Misumi S, Otsuka M, Fujita M, and Ciftci H.
Hydrazonylthiazole derivatives as dual EGFR and ALR2 inhibitors: Design, synthesis, and comprehensive in vitro and in silico evaluation for potential anticancer activity.
Pharmaceuticals 19:50, 2026.
